Question 1

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

Question 3

What is the schedule for visits and treatments during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific eligibility criteria I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer clinical trial (NCT05014776). Contact the study team or your healthcare provider for specific answers.

What this study is about